Edition:
United States

bluebird bio Inc (BLUE.OQ)

BLUE.OQ on NASDAQ Stock Exchange Global Select Market

128.75USD
22 Sep 2017
Change (% chg)

$0.90 (+0.70%)
Prev Close
$127.85
Open
$127.55
Day's High
$130.50
Day's Low
$127.00
Volume
154,726
Avg. Vol
305,943
52-wk High
$136.85
52-wk Low
$37.05

Select another date:

Wed, Sep 20 2017

BRIEF-Bluebird Bio appoints Mary Lynne Hedley, Ph.D. to board of directors

* Bluebird Bio appoints Mary Lynne Hedley, Ph.D. to board of directors Source text for Eikon: Further company coverage:

BRIEF-Bluebird Bio Q2 net loss per share $1.73

* Bluebird Bio reports second quarter 2017 financial results and recent operational progress

BRIEF-Bluebird Bio announces pricing of public offering of common stock

* Bluebird Bio announces pricing of public offering of common stock

BRIEF-Bluebird bio reports updated clinical data from starbeam study

* bluebird bio Inc says on June 26, co reported updated clinical data from starbeam study clinical study of its lenti-d product candidate - sec filing

BRIEF-Bluebird Bio, Celgene Corp announce updated clinical results from ongoing first-in-human multicenter study

* Bluebird Bio and Celgene Corporation announce updated clinical results from ongoing first-in-human multicenter study of bb2121 anti-bcma car t cell therapy in relapsed/refractory multiple myeloma at ASCO annual meeting

BRIEF-Bluebird bio Q1 total revenue $6.8 million

* Bluebird bio reports first quarter 2017 financial results and recent operational progress

BRIEF-Bluebird Bio entered into a worldwide license agreement around its proprietary lentiviral vector platform with Novartis Pharma

* Bluebird bio inc- entered into a worldwide license agreement around its proprietary lentiviral vector platform with novartis pharma ag

BRIEF-Bluebird Bio enters into patent license agreement with Glaxosmithkline for commercialization of Gene Therapies

* Bluebird bio enters lentiviral vector patent license agreement with Glaxosmithkline for commercialization of gene therapies

BRIEF-Bluebird Bio CEO's 2016 compensation was $4.9 mln

* CEO Nick Leschly's 2016 total compensation was $4.9 million versus $11.2 million in 2015 - sec filing Source text - http://bit.ly/2pmsOYK Further company coverage:

Select another date: